基石药业-B遭执行董事胡正国减持22.3万股
CSTONE PHARMACSTONE PHARMA(HK:02616) Ge Long Hui·2025-09-11 00:42

Group 1 - The core point of the news is that Hu Zhengguo, an executive director of Basetone Pharmaceuticals-B (02616.HK), reduced his shareholding by selling 223,000 shares at an average price of HKD 12.007 per share, amounting to approximately HKD 2.678 million [1][2]. - After the sale, Hu Zhengguo's total shareholding decreased to 2.471 million shares, resulting in a reduction of his ownership percentage from 0.18% to 0.17% [1][2].